Ibutamoren mesylate

A non-peptidic, poten and selective, orally-active agonist of the ghrelin receptor (GHSR) with EC50 of 1.3 nM (releases GH from rat pituitary cells) ; significantly increased peak GH concentrations 20.4-fold at 0.25 mg/kg in beagles; has shown to sustain activation of GH-IGF-1 Axis and increase in lean body mass but no change in total fat mass or visceral fat.Growth Hormone Deficiency Phase 2 Clinical (In Vivo) :Ibutamoren mesylate (5 mg/kg/day) results in a statistically significant increases body weight gain and increases serum IGF-1 and GH levels in dogs. Ibutamoren mesylate results in no significant increase in CSF IGF-1 or GH levels on days 7 or 15 of the study. Pretreating mice with GH blocks activation of these neurons by Ibutamoren mesylate (50 μg, i.p.) . In the knockout mice, both GH and octreotide fail to inhibit Ibutamoren mesylate activation of arcuate neurons. Chronic oral administration of MK-0677 is associated with significant increases in GH and IGF-I levels that are maintained for the duration of the treatment. The GH profile following MK-0677 administration consists of episodic increases above control. MK-0677 significantly increases peak GH concentrations after oral administration. MK-0677 is a potent GH secretagogue that induces an immediate, large, long lasting increase in GH levels when administered orally or i.v.